BURNING ROCK BIOTECH LTD-ADR (BNR) Stock Fundamental Analysis

NASDAQ:BNR • US12233L2060

29.135 USD
-1.13 (-3.75%)
At close: Feb 13, 2026
29 USD
-0.14 (-0.46%)
After Hours: 2/13/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall BNR gets a fundamental rating of 2 out of 10. We evaluated BNR against 523 industry peers in the Biotechnology industry. BNR has a bad profitability rating. Also its financial health evaluation is rather negative. BNR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • BNR had negative earnings in the past year.
  • In the past year BNR has reported a negative cash flow from operations.
  • BNR had negative earnings in each of the past 5 years.
  • In the past 5 years BNR always reported negative operating cash flow.
BNR Yearly Net Income VS EBIT VS OCF VS FCFBNR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M -800M

1.2 Ratios

  • BNR has a Return On Assets of -14.93%. This is in the better half of the industry: BNR outperforms 79.92% of its industry peers.
  • BNR has a Return On Equity of -22.06%. This is amongst the best in the industry. BNR outperforms 82.03% of its industry peers.
Industry RankSector Rank
ROA -14.93%
ROE -22.06%
ROIC N/A
ROA(3y)-54.4%
ROA(5y)-43.17%
ROE(3y)-76.2%
ROE(5y)-58.25%
ROIC(3y)N/A
ROIC(5y)N/A
BNR Yearly ROA, ROE, ROICBNR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

  • Looking at the Gross Margin, with a value of 73.02%, BNR belongs to the top of the industry, outperforming 82.60% of the companies in the same industry.
  • BNR's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for BNR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y-0.38%
BNR Yearly Profit, Operating, Gross MarginsBNR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • BNR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for BNR remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, BNR has more shares outstanding
  • BNR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BNR Yearly Shares OutstandingBNR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
BNR Yearly Total Debt VS Total AssetsBNR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • BNR has an Altman-Z score of -1.55. This is a bad value and indicates that BNR is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of BNR (-1.55) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.00 indicates that BNR is not too dependend on debt financing.
  • BNR's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. BNR outperforms 48.37% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.55
ROIC/WACCN/A
WACC11.11%
BNR Yearly LT Debt VS Equity VS FCFBNR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

2.3 Liquidity

  • A Current Ratio of 3.14 indicates that BNR has no problem at all paying its short term obligations.
  • With a Current ratio value of 3.14, BNR is not doing good in the industry: 62.72% of the companies in the same industry are doing better.
  • A Quick Ratio of 2.91 indicates that BNR has no problem at all paying its short term obligations.
  • BNR has a worse Quick ratio (2.91) than 62.91% of its industry peers.
Industry RankSector Rank
Current Ratio 3.14
Quick Ratio 2.91
BNR Yearly Current Assets VS Current LiabilitesBNR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • BNR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 93.72%, which is quite impressive.
  • The Revenue has been growing slightly by 5.56% in the past year.
  • The Revenue has been growing slightly by 6.21% on average over the past years.
EPS 1Y (TTM)93.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.1%
Revenue 1Y (TTM)5.56%
Revenue growth 3Y0.52%
Revenue growth 5Y6.21%
Sales Q2Q%2.31%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • The Revenue is expected to grow by 15.51% on average over the next years. This is quite good.
EPS Next Y-277.41%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year48.35%
Revenue Next 2Y17.89%
Revenue Next 3Y16.85%
Revenue Next 5Y15.51%

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BNR Yearly Revenue VS EstimatesBNR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
BNR Yearly EPS VS EstimatesBNR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BNR. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BNR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNR Price Earnings VS Forward Price EarningsBNR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNR Per share dataBNR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for BNR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BURNING ROCK BIOTECH LTD-ADR

NASDAQ:BNR (2/13/2026, 8:00:01 PM)

After market: 29 -0.14 (-0.46%)

29.135

-1.13 (-3.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-02
Earnings (Next)03-23
Inst Owners24.14%
Inst Owner Change1%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap298.89M
Revenue(TTM)539.27M
Net Income(TTM)-121.25M
Analysts80
Price TargetN/A
Short Float %0.95%
Short Ratio1.23
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.83
P/FCF N/A
P/OCF N/A
P/B 3.76
P/tB 3.76
EV/EBITDA N/A
EPS(TTM)-1.76
EYN/A
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS7.61
BVpS7.75
TBVpS7.75
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.93%
ROE -22.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.02%
FCFM N/A
ROA(3y)-54.4%
ROA(5y)-43.17%
ROE(3y)-76.2%
ROE(5y)-58.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y-0.38%
F-Score5
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.14
Quick Ratio 2.91
Altman-Z -1.55
F-Score5
WACC11.11%
ROIC/WACCN/A
Cap/Depr(3y)26.43%
Cap/Depr(5y)152.99%
Cap/Sales(3y)5.44%
Cap/Sales(5y)15.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.1%
EPS Next Y-277.41%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)5.56%
Revenue growth 3Y0.52%
Revenue growth 5Y6.21%
Sales Q2Q%2.31%
Revenue Next Year48.35%
Revenue Next 2Y17.89%
Revenue Next 3Y16.85%
Revenue Next 5Y15.51%
EBIT growth 1Y79.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y89.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y89.46%
OCF growth 3YN/A
OCF growth 5YN/A

BURNING ROCK BIOTECH LTD-ADR / BNR FAQ

Can you provide the ChartMill fundamental rating for BURNING ROCK BIOTECH LTD-ADR?

ChartMill assigns a fundamental rating of 2 / 10 to BNR.


Can you provide the valuation status for BURNING ROCK BIOTECH LTD-ADR?

ChartMill assigns a valuation rating of 0 / 10 to BURNING ROCK BIOTECH LTD-ADR (BNR). This can be considered as Overvalued.


What is the profitability of BNR stock?

BURNING ROCK BIOTECH LTD-ADR (BNR) has a profitability rating of 2 / 10.


What is the earnings growth outlook for BURNING ROCK BIOTECH LTD-ADR?

The Earnings per Share (EPS) of BURNING ROCK BIOTECH LTD-ADR (BNR) is expected to decline by -277.41% in the next year.